The purpose of this study is to examine how patients with multiple myeloma (MM) have been impacted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The study will use a questionnaire to further understand how patients are being affected and gather information in order to track the long-term effects of the coronavirus. The scope of the questionnaire will include, COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life. This questionnaire is a follow-on to the "MM and COVID-19" questionnaire.
Behavioral: Questionnaire
Series of questions covering COVID-19 diagnosis and treatment, changes in myeloma treatment and care, clinical trial familiarity, health and fitness, and quality of life.
Inclusion Criteria:
- Adult patients (greater than 18 years) diagnosed with MGUS, smoldering myeloma, and
multiple myeloma.
- Access to a computer or electronic device with internet access, or phone
- Willing to create a patient profile on the HealthTree Cure Hub For Multiple Myeloma
- Willing to give electronically-signed consent
- Ability to read questions in English
HealthTree.org (Online)
Lehi, Utah, United States
Investigator: Nathan Sweeney, PhD
Contact: 800-709-1113
nathan@healthtree.org
Nathan Sweeney, PhD
18007091113
nathan@healthtree.org
Nathan Sweeney, PhD, Study Chair
HealthTree Foundation